Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Invitrogen

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 23 February 2007:
Vol. 315. no. 5815, pp. 1149 - 1153
DOI: 10.1126/science.315.5815.1149
Prev | Table of Contents | Next

From the AAAS Office of Publishing and Member Services

BUSINESS OFFICE FEATURE:
Clinical Proteomics: Coming to Terms with Complexity

Monya Baker

Proteomics can explore what is going on (or going wrong) in a particular tissue at a particular time. Such knowledge can help to develop diagnostics and to select compounds and doses for clinical trials. But selecting the information to use is a conundrum. Protein content varies from cell to cell and minute to minute. Abundant proteins mask the presence of rare but key proteins. It is hard enough to find reliable differences between disease and health or between patients likely to be helped by a drug and those likely to be harmed by it. Even harder is homing in on the differences that really matter.




ADVERTISEMENT
Click Me!

ADVERTISEMENT
Click Me!

To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)